Novaliq GmbH Receives € 2.3 Million Funding

Published: Jul 27, 2011

Heidelberg, Germany -- Novaliq GmbH a drug delivery company with focus on technologies for poorly soluble drugs for ophthalmic and topical applications has today announced the successfully completion of a financing round of € 2.3 Mio. Since its foundation in the year 2004 the company has raised € 9,3 Million in three finance rounds.

Investor is again the investment company of SAP co-founder Dietmar Hopp, dievini Hopp Bio Tech holding GmbH & Co. KG. With the new funds the company intends to advance its lead projects into clinical development and to strengthen and broaden the technology platform.

“We are pleased about the ongoing confidence and support from our investor in order to systematically develop the company with our technology platform”, Bernhard Günther, Managing Director and co-founder of Novaliq says.

“Since its foundation Novaliq has developed in line with the business plan and even better. We see a big potential and numerous applications for the technology platform which we continue to support with this new financing” says Friedrich von Bohlen. Managing Director of dievini.

About Novaliq

NOVALIQ GmbH is a drug delivery company whose goal is to develop innovative pharmaceutical formulations. The patented semifluorinated alkanes (SFAs) can be used in various routes of administration for the transport of drugs or oxygen for therapeutic purposes. Based on its unique physicochemical properties, Novaliq currently develops innovative ophthalmic and dermatological formulations as well as solutions for organ preservation and has several product candidates with excellent market potential in various stages of preclinical and clinical development.

Back to news